Drug approved for inherited blood disorder

(HealthDay)—Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release.

Thalassemia typically leads to the production of fewer and less hemoglobin, a protein that carries oxygen throughout the body. NTDT is a milder form of thalassemia that unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.

The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.

The drug is produced by Novartis, East Hanover, N.J.


Explore further

Blood protein offers help against anemia

More information: The U.S. National Heart Lung and Blood Institute has more about thalassemia.

More Information

Health News Copyright © 2013 HealthDay. All rights reserved.

Citation: Drug approved for inherited blood disorder (2013, January 24) retrieved 25 June 2019 from https://medicalxpress.com/news/2013-01-drug-inherited-blood-disorder.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more